Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | ARID1B dec exp |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
ARID1B dec exp | Advanced Solid Tumor | predicted - sensitive | Cisplatin | Preclinical - Cell culture | Emerging | In a preclinical study, siRNA knockdown of ARID1B in cultured tumor cells resulted in increased sensitivity to Platinol (cisplatin), suggesting that tumors with ARID1B loss or inactivation may have increased response to DNA damaging agents (PMID: 24788099). | 24788099 |